LAB282: two years of drug discovery impact

LAB282, a unique funding-expertise hybrid model to accelerate Oxford therapeutics out of the lab and into the wider world, launched two years ago this month. When it was conceived, LAB282 was a unique concept to accelerate therapeutics research emerging from Oxford...

read more

LAB282 celebrates a year of impact in Oxford

The £13m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec supported 12 new projects in first year of operation. LAB282, the £13m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec, is...

read more

LAB282 – accelerating drug discovery at Oxford

Oxford University, Oxford University Innovation, Oxford Sciences Innovation and Evotec announce a new partnership to advance the development of next-generation medicines arising from Oxford research. Called ‘LAB282’, the partnership will provide a £13m fund, open now...

read more

Lab282 Partners

LAB282 is a partnership between the University of Oxford, Oxford University Innovation Ltd, Oxford Sciences Innovation plc (OSI) and Evotec AG, created to identify and develop new approaches to treating disease.

Privacy Policy | Cookie Policy

© LAB282 2019. All rights reserved
LAB282 is a partnership between the University of Oxford, Oxford University Innovation Ltd, Oxford Sciences Innovation plc (OSI) and Evotec AG, created to identify and develop new approaches to treating disease.

Privacy Policy | Cookie Policy

© LAB282 2019. All rights reserved